Aimovig® is indicated for the preventive treatment of migraine in adults.
You are about to leave the aimovighcp.com website and enter a website operated by a third party. Amgen & Novartis are not responsible for and do not endorse or control the content contained on this third-party website.
Aimovig® is the #1 prescribed anti-CGRP therapy in the US, with over 2 million prescriptions written1,*
AHS treatment guidance for migraine patients
Helping your patients get the resources to start Aimovig®
Pivotal and long-term data: Reductions in monthly migraine days
≥50% and ≥75% Reductions in monthly migraine days
Aimovig® data in patients with prior oral preventive failure
AHS guidance for treating migraine
Aimovig® dosing and administration
Aimovig® pivotal and long-term safety data
Starting patients on Aimovig®
Access and affordability